Pharmicell (005690) - Net Assets
Based on the latest financial reports, Pharmicell (005690) has net assets worth ₩110.43 Billion KRW (≈ $74.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩130.02 Billion ≈ $88.12 Million USD) and total liabilities (₩19.60 Billion ≈ $13.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pharmicell liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩110.43 Billion |
| % of Total Assets | 84.93% |
| Annual Growth Rate | 16.73% |
| 5-Year Change | 51.37% |
| 10-Year Change | 4.88% |
| Growth Volatility | 203.57 |
Pharmicell - Net Assets Trend (2010–2024)
This chart illustrates how Pharmicell's net assets have evolved over time, based on quarterly financial data. Also explore 005690 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Pharmicell (2010–2024)
The table below shows the annual net assets of Pharmicell from 2010 to 2024. For live valuation and market cap data, see 005690 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩86.44 Billion ≈ $58.58 Million |
+7.52% |
| 2023-12-31 | ₩80.40 Billion ≈ $54.48 Million |
+4.87% |
| 2022-12-31 | ₩76.66 Billion ≈ $51.95 Million |
+20.03% |
| 2021-12-31 | ₩63.87 Billion ≈ $43.28 Million |
+11.85% |
| 2020-12-31 | ₩57.11 Billion ≈ $38.70 Million |
+10.84% |
| 2019-12-31 | ₩51.52 Billion ≈ $34.91 Million |
+8.48% |
| 2018-12-31 | ₩47.49 Billion ≈ $32.18 Million |
-15.19% |
| 2017-12-31 | ₩55.99 Billion ≈ $37.95 Million |
-40.81% |
| 2016-12-31 | ₩94.60 Billion ≈ $64.11 Million |
+14.77% |
| 2013-12-31 | ₩82.42 Billion ≈ $55.86 Million |
-18.86% |
| 2012-12-31 | ₩101.58 Billion ≈ $68.84 Million |
+22.65% |
| 2011-12-31 | ₩82.82 Billion ≈ $56.13 Million |
+736.15% |
| 2010-12-31 | ₩9.90 Billion ≈ $6.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmicell's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2555628099000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩7.13 Billion | 8.25% |
| Other Components | ₩79.31 Billion | 91.75% |
| Total Equity | ₩86.44 Billion | 100.00% |
Pharmicell Competitors by Market Cap
The table below lists competitors of Pharmicell ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Magic Software Enterprises Ltd
TA:MGIC
|
$736.62 Million |
|
Wuhan Sanzhen Industry Holding Co Ltd
SHG:600168
|
$737.00 Million |
|
GH RESEARCH PLC DL-025
F:1KA
|
$737.24 Million |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
$737.34 Million |
|
Minerva S.A
SA:BEEF3
|
$736.26 Million |
|
EuroTeleSites AG
F:7YF
|
$735.93 Million |
|
Sichuan Xichang Electric Power Co Ltd
SHG:600505
|
$735.13 Million |
|
BETTER COLLECTIVE EO-01
F:9C8
|
$735.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmicell's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 80,396,946,740 to 86,439,170,270, a change of 6,042,223,530 (7.5%).
- Net income of 6,331,277,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.33 Billion | +7.32% |
| Other Changes | ₩-289.05 Million | -0.33% |
| Total Change | ₩- | 7.52% |
Book Value vs Market Value Analysis
This analysis compares Pharmicell's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.89x to 12.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩958.87 | ₩18110.00 | x |
| 2018-12-31 | ₩792.21 | ₩18110.00 | x |
| 2019-12-31 | ₩859.43 | ₩18110.00 | x |
| 2020-12-31 | ₩952.61 | ₩18110.00 | x |
| 2021-12-31 | ₩1065.48 | ₩18110.00 | x |
| 2022-12-31 | ₩1277.66 | ₩18110.00 | x |
| 2023-12-31 | ₩1339.86 | ₩18110.00 | x |
| 2024-12-31 | ₩1440.56 | ₩18110.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmicell utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.76%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.15x
- Recent ROE (7.32%) is above the historical average (-17.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -119.56% | -164.31% | 0.24x | 3.00x | ₩-12.85 Billion |
| 2011 | -21.94% | -176.74% | 0.10x | 1.22x | ₩-26.46 Billion |
| 2012 | -17.36% | -158.77% | 0.08x | 1.34x | ₩-27.80 Billion |
| 2013 | -31.17% | -76.94% | 0.34x | 1.21x | ₩-33.95 Billion |
| 2016 | -0.72% | -2.43% | 0.27x | 1.08x | ₩-10.14 Billion |
| 2017 | -70.00% | -155.56% | 0.40x | 1.14x | ₩-44.80 Billion |
| 2018 | -26.70% | -44.73% | 0.48x | 1.24x | ₩-17.43 Billion |
| 2019 | 8.44% | 13.38% | 0.51x | 1.23x | ₩-804.78 Million |
| 2020 | 9.18% | 13.88% | 0.54x | 1.22x | ₩-468.72 Million |
| 2021 | 14.80% | 18.24% | 0.55x | 1.48x | ₩3.06 Billion |
| 2022 | 10.78% | 13.73% | 0.55x | 1.43x | ₩595.28 Million |
| 2023 | 4.45% | 6.36% | 0.61x | 1.15x | ₩-4.46 Billion |
| 2024 | 7.32% | 9.76% | 0.65x | 1.15x | ₩-2.31 Billion |
Industry Comparison
This section compares Pharmicell's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $403,801,694,881
- Average return on equity (ROE) among peers: 0.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmicell (005690) | ₩110.43 Billion | -119.56% | 0.18x | $736.42 Million |
| ORIENTBIO Inc. (002630) | $57.60 Billion | 0.00% | 0.70x | $43.15 Million |
| Green Cross (005250) | $1.51 Trillion | 0.20% | 0.84x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.85 Trillion | 1.30% | 0.98x | $3.74 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $77.34 Million |
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more